摘要
目的本研究通过对连花清瘟两味君药连翘和金银花进行网络药理分析,明确其在该方剂中治疗COVID-19的地位,探究其靶点及信号通路,阐明其作用机制。方法通过中药系统药理数据库和分析平台和Genecards数据库分别对连翘和金银花进行有效成分分析和COVID-19潜在靶基因的筛选。运用STRING数据库构建PPI网络和Cytoscape软件构建活性成分-靶点网络,通过DAVID数据库对靶点进行功能和通路富集分析。结果两味君药有效活性成分共42个,总活性成分靶基因242个,其中52个是COVID-19的潜在治疗靶标,与整个方剂靶基因库高度重合。富集到基因功能主要涉及生物过程。通路包含炎症反应,外源性凋亡信号通路,细胞对脂多糖的反应和肿瘤坏死因子信号通路等。结论连翘和金银花是连花清瘟发挥治疗作用的关键药物,主要通过酮类和植物甾醇类活性成分调节关键靶点,调控炎症反应、细胞凋亡、介导免疫反应等过程减轻肺损伤来治疗COVID-19,同时也提示以其为基础的其他相关中药方剂的开发有望成为COVID-19治疗的关键。
OBJECTIVE To explore the mechanism of two monarch drugs, forsythia and honeysuckle of Lianhuaqingwen in the treatment of COVID-19 through the network pharmacological analysis, to clarify their role in the treatment of COVID-19 in this prescription and to explore the targets and signal pathways and mechanism. METHODS COVID-19 potential target genes and effective components of forsythia and honeysuckle were screened by traditional chinese medicin system pharmacological database and Genecards database. The construction of PPI network, active component-target network, the analysis of function enrichment were carried out with STRING database, Cytoscape, DAVID database respectively. RESULTS The two herbs contained 42 effective components and 242 related active-component target genes, of which 52 potential targets act on COVID-19, which were highly overlapped with the entire target genes database of the prescription. The collected genes function were mainly involved in biological processes. The pathways included inflammatory response, exogenous apoptosis signaling pathway, cell response to lipopolysaccharide and tumor necrosis factor signaling pathway. CONCLUSION Forsythia and honeysuckle are the key herbs in Lianhuaqingwen, which will regulate and mediate the inflammation, cell apoptosis, immune response and other processes through the active components of ketones and phytosterols acting as key targets to reduce lung injury and treat COVID-19. It also suggests that other traditional Chinese medicine prescriptions based on this two herbs will become key points for the treatment of COVID-19.
作者
陈爽
汪静
吴栋丽
张述耀
CHEN Shuang;WANG Jing;WU Dongli;ZHANG Shuyao(Department of Pharmacology,Shantou University Medical College,Shantou,Guangdong 515000,China;Department of Pharmacy,Guangzhou Red Cross Hospital,Jinan University,Guangzhou,Guangdong 510000,China;Department of Pharmacy,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangzhou,Guangdong 510000,China)
出处
《今日药学》
CAS
2021年第4期263-270,共8页
Pharmacy Today
基金
2018年广东省科技创新战略专项资金(纵向协同管理方向)项目[汕府科(2018)157号]。
